Floatz logo

hs-10516

Advanced Renal Cell Carcinoma

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 1/2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
81/ 100

Competitive context

18 Active assets in the Advanced Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Trebananib
National Cancer Institute (NCI)
Phase 2BB
CLOSTRIDIUM BUTYRICUM MIYAIRI 588
City of Hope Medical Center
Phase 3BB
Bms-907351
National Cancer Institute (NCI)
Phase 2B
Telaglenastat
Calithera Biosciences, Inc
Phase 2B
Dfn-15
Case Comprehensive Cancer Center
Phase 2B

View all 32 →

Same molecule, other indications

hs-10516 is also rated in:

nonpapillary renal cell carcinomaDormant
CC
Indicative ·
45 / 100
View asset →
renal cell carcinomaDormant
C
Indicative ·
37 / 100
View asset →
clear cell renal carcinomaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →